NCT01020305: Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer |
|
|
| Terminated | 1/2 | 5 | US | Temsirolimus, Torisel, CCI-779, Casodex (bicalutamide), Casodex, bicalutamide, Cosudex, Calutide, Kalumid | Sandy Srinivas, Wyeth is now a wholly owned subsidiary of Pfizer, National Comprehensive Cancer Network, American Society of Clinical Oncology | Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer, Hormone-refractory Prostate Cancer, Metastatic Disease | 04/12 | 04/12 | | |
